Relevant bibliographies by topics / Narrow therapeutic index drugs

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Narrow therapeutic index drugs'

Author: Grafiati
Published: 4 June 2021
Last updated: 5 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Narrow therapeutic index drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Narrow therapeutic index drugs"

1

Ali, Huma, Farya Zafar, Ahmed Shaukat, et al. "NARROW THERAPEUTIC INDEX DRUGS;." Professional Medical Journal 24, no. 04 (2017): 596–606. http://dx.doi.org/10.29309/tpmj/2017.24.04.1460.

Full text
Abstract:
Introduction: There are several clinically significant outcomes of drug-druginteractions (DDIs) which have been classified as one of the serious forms of adverse drugreactions that may lead to prolongation of hospital stays along with severe cases of mortality andmorbidities. It may cause due to the selection of two or more interacting drugs to be prescribedto patient. Objectives: Therefore it is indispensable to attain a collective level of therapeuticdecision making so that any potential DDIs can be minimized that ultimately turn out to be safeand beneficial to patient. Study Design: The cur
APA, Harvard, Vancouver, ISO, and other styles
2

Levy, Gerhard. "What are narrow therapeutic index drugs?" Clinical Pharmacology & Therapeutics 63, no. 5 (1998): 501–5. http://dx.doi.org/10.1016/s0009-9236(98)90100-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Habet, Sam. "Narrow Therapeutic Index drugs: clinical pharmacology perspective." Journal of Pharmacy and Pharmacology 73, no. 10 (2021): 1285–91. http://dx.doi.org/10.1093/jpp/rgab102.

Full text
Abstract:
Abstract Objectives Historically, the identification of drugs with the Narrow Therapeutic Index (NTI) has been empirically based on the clinical practice. In general terms, NTI drugs can be defined based on the steepness of the dose–response relationship and the degree of overlap between the effective and the toxic concentrations. Key findings The current definition in the Code of Federal Regulations is based on animal data and as such lacks direct clinical relevance. By basing these criteria on those factors that affect the degree of separation of the concentrations that elicit the therapeuti
APA, Harvard, Vancouver, ISO, and other styles
4

Baumgärtel, Christoph, and Brian Godman. "Bioequivalence of narrow therapeutic index drugs and immunosuppressives." Generics and Biosimilars Initiative Journal 4, no. 4 (2015): 159–60. http://dx.doi.org/10.5639/gabij.2015.0404.035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Benet, L. Z. "Relevance of pharmacokinetics in narrow therapeutic index drugs." Transplantation Proceedings 31, no. 3 (1999): 1642–44. http://dx.doi.org/10.1016/s0041-1345(99)00083-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Yu, LX, W. Jiang, X. Zhang, et al. "Novel bioequivalence approach for narrow therapeutic index drugs." Clinical Pharmacology & Therapeutics 97, no. 3 (2014): 286–91. http://dx.doi.org/10.1002/cpt.28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jayachandran, Priya, Hideaki Okochi, Lynda A. Frassetto, et al. "Evaluating Within‐Subject Variability for Narrow Therapeutic Index Drugs." Clinical Pharmacology & Therapeutics 105, no. 2 (2019): 411–16. http://dx.doi.org/10.1002/cpt.1293.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tamargo, Juan, Jean-Yves Le Heuzey, and Phillipe Mabo. "Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide." European Journal of Clinical Pharmacology 71, no. 5 (2015): 549–67. http://dx.doi.org/10.1007/s00228-015-1832-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Liang, Bryan A., Tim K. Mackey, and Kimberly M. Lovett. "Illegal “No Prescription” Internet Access to Narrow Therapeutic Index Drugs." Clinical Therapeutics 35, no. 5 (2013): 694–700. http://dx.doi.org/10.1016/j.clinthera.2013.03.019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Johnston, Atholl. "Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation." European Journal of Hospital Pharmacy 20, no. 5 (2013): 302–7. http://dx.doi.org/10.1136/ejhpharm-2012-000258.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Narrow therapeutic index drugs"

1

Minkutė, Rima. "Klinikinės farmacijos paslaugos poreikio tyrimas stacionarinio gydymo įstaigose optimizuojant siauro terapinio indekso vaistų vartojimą." Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2014. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2014~D_20140904_150038-39448.

Full text
Abstract:
Siauro terapinio indekso vaistų vartojimas ir farmakokinetikos tyrimų interpretavimas reikalauja specialių farmakokinetikos žinių. Mokslinės literatūros šaltiniuose teigiama, jog gydymo procese dalyvaujant klinikiniams vaistininkams vaistų vartojimas yra optimizuojamas. Lietuvoje panašios vaistininkų veiklos nėra, todėl tyrimo tikslas buvo įvertinti siauro terapinio indekso vaistų vartojimo racionalumą ir nustatyti klinikinės farmacijos paslaugos poreikį stacionarinio gydymo įstaigoje. Darbo uždaviniai: nustatyti ir įvertinti farmakoterapinių problemų, siejamų su siauro terapinio indekso vaist
APA, Harvard, Vancouver, ISO, and other styles
2

Andrade, Glauber Ant?nio dos Reis. "Determina??o da teofilina, clindamicina, varfarina e verapamil por amperometria pulsada em sistema de an?lise por inje??o em batelada usando o eletrodo de diamante dopado com boro." UFVJM, 2016. http://acervo.ufvjm.edu.br/jspui/handle/1/1131.

Full text
Abstract:
?rea de concentra??o: Qu?mica anal?tica.<br>Submitted by Jos? Henrique Henrique (jose.neves@ufvjm.edu.br) on 2016-12-21T13:02:41Z No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) glauber_antonio_reis_andrade.pdf: 2400963 bytes, checksum: 99ec593844d6ba3a1107158d86656739 (MD5)<br>Approved for entry into archive by Rodrigo Martins Cruz (rodrigo.cruz@ufvjm.edu.br) on 2017-01-21T11:09:00Z (GMT) No. of bitstreams: 2 license_rdf: 9 bytes, checksum: 42dd12a06de379d3ffa39b67dc9c7aff (MD5) glauber_antonio_reis_andrade.pdf: 2400963 bytes, checksum: 99ec593844d6
APA, Harvard, Vancouver, ISO, and other styles
3

Jones, Alison. "Modulation of the therapeutic index of chemotherapy and radiotherapy by cytotoxic drugs and biological agents." Thesis, University of Bristol, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.299808.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

La, Rosa Rodríguez Emilio. "Bioética, medicamentos, conflicto de intereses y control de calidad." Pontificia Universidad Católica del Perú, 2012. http://repositorio.pucp.edu.pe/index/handle/123456789/115762.

Full text
Abstract:
Bioethics, medicines, interests conflict and quality controlThe article analyzes the problems of pharmaceutical advertising that distorts, exaggerates or hides certain information (side effects of drugs), as well as the work of pharmaceutical sales  representatives, the problem of drugs’ risk, marketing authorization, access to drugs, therapeutic practice, conflicts of interest, and quality control in medicine. These issues have a greater importance in public health; since the lack of respect for the fundamental principles of bioethics (benefit, not harm, autonomy and consent) has a direct imp
APA, Harvard, Vancouver, ISO, and other styles
5

Patel, Krupa J. "Distribution of Anti-cancer Drugs within Solid Tumours and Normal Tissues and its Potential for Modification to Improve Therapeutic Index." Thesis, 2011. http://hdl.handle.net/1807/29837.

Full text
Abstract:
Anti-cancer drugs gain access to solid tumors via the blood, and must penetrate tissue to reach all viable cancer cells. This thesis aims to compare the distribution of anticancer drugs in normal tissues and tumours, to examine whether drug distribution is modifiable and quantifiable in solid tumours, and to determine whether extracellular drug distribution can be improved by modifying intracellular drug distribution. The time-dependent spatial distribution of three anticancer drugs, doxorubicin, mitoxantrone and topotecan, were studied in normal tissues and tumours. Ten minutes after drug
APA, Harvard, Vancouver, ISO, and other styles
6

Rodrigues, Márcio José de Abreu Marques. "Evaluation of the effect of herbal extracts used in slimming regimens in the kinetic profile of narrow therapeutic range drugs used for cardiovascular pathologies: the amiodarone." Doctoral thesis, 2013. http://hdl.handle.net/10316/24327.

Full text
Abstract:
Tese de doutoramento em Ciências Farmacêuticas, na especialidade de Farmacologia e Farmacoterapia, apresentada à Faculdade de Farmácia da Universidade de Coimbra<br>The use of plants for the prevention and treatment of various health diseases has been a practice that comes from the ancient civilizations. However, in recent years has been observed an increase in the use of herbal products. In developed countries is particularly worrying the increasing consumption of herbal weight loss medicines/dietary supplements as alternative or complement to the traditional programs of body weight reduction
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Narrow therapeutic index drugs"

1

Cavanna, Andrea E. Phenytoin. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198791577.003.0010.

Full text
Abstract:
Phenytoin is a first-generation antiepileptic drug characterized by a good range of antiepileptic indications, with an acceptable interaction profile in polytherapy. The reasons for the decreased use of phenytoin in patients with epilepsy include its narrow therapeutic index and potential for long-term toxicity, as well as the development of other antiepileptic drugs throughout the second half of the twentieth century. Phenytoin has a good behavioural tolerability profile and a restricted range of psychiatric uses. Despite occasional reports of adverse behavioural effects (especially at higher
APA, Harvard, Vancouver, ISO, and other styles
2

Fudin, Jeffrey, Jacqueline Cleary, Courtney Kominek, Abigail Brooks, and Thien C. Pham. Screening Patients for Opioid Risk (DRAFT). Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190265366.003.0010.

Full text
Abstract:
The narrow therapeutic index associated with most analgesic opioids creates a high degree of risk, obliging caution in patient selection; this chapter describes screening practices. More attention is due to the use of opioid therapy for chronic non-cancer pain as episodes of respiratory arrest increase. Universal precautions are recommended for all patients. Before and throughout treatment, selected tools assessing risk and misuse should be employed. Increased access to the opioid antagonist naloxone has followed the increase in opioid poisoning deaths; the Risk Index for Overdose or Serious O
APA, Harvard, Vancouver, ISO, and other styles
3

Waldmann, Carl, Neil Soni, and Andrew Rhodes. Haematological drugs. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199229581.003.0014.

Full text
Abstract:
Anticoagulants and heparin-induced thrombocytopenia 220Thrombolysis 224Antifibrinolytics 226For &gt;50 years, the options for therapeutic anticoagulation were limited to unfractionated heparin (UFH) and oral vitamin K antagonists. While highly effective, both drugs have major safety problems. Both have narrow therapeutic ranges, substantial interindividual dose variability, major side effects and require regular therapeutic drug monitoring, with a narrow therapeutic window and high incidence of bleeding complications....
APA, Harvard, Vancouver, ISO, and other styles
4

Lance, Leonard L. Drug Information Handbook for the Allied Health Professional: With Indication/Therapeutic Category Index : 2001. 8th ed. Lexi-Comp, Inc., 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Inhibitor Index: A Desk Reference on Enzyme Inhibitors, Receptor Antagonists, Drugs, Toxins, Poisons, Biologics, and Therapeutic Leads. Taylor & Francis Group, 2017.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Drug Information Handbook for the Allied Health Professional: With Indication/Therapeutic Category Index : 1999-2000 (Lexi-Comp's Clinical Reference Library). 6th ed. Lexi-Comp, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lazar, Alina. Perioperative Epidural Pain Management in Children. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190271787.003.0040.

Full text
Abstract:
In adults, the postoperative benefits of epidural analgesia are well established, but in children the literature is sparse and controversy exists about the benefits, risks, ideal placement technique, and dosage of medication infused epidurally. Little is known about the neurotoxicity of various medications currently administered in the epidural space or the long-term consequences of epidural analgesia. The management of epidural analgesia in children is complicated by the narrow therapeutic window of epidural drugs, especially in neonates and young infants, and the difficulties of evaluating p
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Narrow therapeutic index drugs"

1

Jiang, Wenlei, and Lawrence X. Yu. "Bioequivalence for Narrow Therapeutic Index Drugs." In FDA Bioequivalence Standards. Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1252-0_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Generic Substitution of Narrow Therapeutic Index Drugs (0817)." In Best Practices. American Society of Health-System Pharmacists, 2019. http://dx.doi.org/10.37573/9781585286560.100.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sefton, Armine. "Use of Antimicrobials and Toxicity." In Tutorial Topics in Infection for the Combined Infection Training Programme. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780198801740.003.0054.

Full text
Abstract:
Broad-spectrum antibacterial agents kill most bacteria including gram-positive rods and cocci, gram-negative rods and cocci, and often anaerobes too. Narrow-spectrum agents kill a narrow range of microbes, e.g. benzylpenicillin is mainly active against gram-positive cocci. By and large a narrow-spectrum antimicrobial is less likely to disrupt a patient’s normal flora than a broad-spectrum agent. Hence, if the likely organism is causing an infection it is best to give a narrow-spectrum antimicrobial to treat that specific organism. If a patient presents ‘septic’ and the source of infection is unknown, relevant cultures should be taken followed by broad-spectrum antimicrobial cover. This can later be modified either when the source of infection is found or as a result of microbiology culture results. ● Agents mostly active against gram-positive bacteria include: ■ Penicillin (Also active against Neisseria spp.). ■ Fusidic acid. ■ Macrolides (Also active against Legionella, Campylobacter, Bordetella spp.). ■ Clindamycin. ■ Glycopeptides. ■ Oxazolidinones. ■ Streptogramins. ● Agents mainly active against gram-negative bacteria include: ■ Polymyxin. ■ Trimethoprim. ■ Aminoglycosides (also active against staphylococci and show synergy when combined with beta-lactams against/glycopeptides against streptococci). ■ Monobactams. ■ Temocillin. ● Broad-spectrum antimicrobials include: ■ Beta-lactam plus beta-lactamase inhibitor combinations. ■ Cephalosporins. ■ Carbapenems. ■ Chloramphenicol, Tetracyclines/Glycyclines. A bactericidal agent is a compound that actively kills multiplying bacteria. A bacteriostatic compound inhibits the growth of bacteria. Whether or not an antimicrobial is bactericidal or bacteriostatic depends on a variety of things, including the type of agent, its concentration, and the organism it is being used to treat. It is especially important to try and use a bactericidal agent if the patient’s immune system is impaired or the infection is at a site where it is difficult for the immune system to access, e.g. the heart valves in bacterial endocarditis, the meninges in meningitis. Examples of each are given here: ● Bactericidal agents include beta-lactams, glycopeptides, fluoroquinolones, and aminoglycosides. ● Bacteriostatic agents include macrolides, clindamycin, tetracyclines, trimethoprim, and sulphonamides. The therapeutic index of a drug is the ration of the concentration of drug likely to be toxic to the patient divided by the concentration of drug likely to be clinically effective.
APA, Harvard, Vancouver, ISO, and other styles
4

"Improving the Therapeutic Index of Antineoplastic Agents through Additional Drugs." In The Benefit/Risk Ratio. CRC Press, 1998. http://dx.doi.org/10.1201/9781439805916-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Singh, Prabhakar, Sudhakar Singh, and Rajesh Kumar Kesharwani. "Resealed Erythrocytes as Drug Carriers and Its Therapeutic Applications." In Pharmaceutical Sciences. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-1762-7.ch018.

Full text
Abstract:
In this pharma innovative world, there are more than 30 drug delivery systems. Today's due to lacking the target specificity, the present scenario about drug delivery is emphasizing towards targeted drug delivery systems. Erythrocytes are the most common type of blood cells travel thousands of miles from wide to narrow pathways to deliver oxygen, drugs and nutrient during their lifetime. Red blood cells have strong and targeted potential carrier capabilities for varieties of drugs. Drug-loaded carrier erythrocytes or resealed erythrocytes are promising for various passive and active targeting. Resealed erythrocyte have advantage over several drug carrier models like biocompatibility, biodegradability without toxic products, inert intracellular environment, entrapping potential for a variety of chemicals, protection of the organism against toxic effects of the drug, able to circulate throughout the body, ideal zero-order drug-release kinetics, no undesired immune response against encapsulated drug etc. Resealed erythrocytes are rapidly taken up by macrophages of the Reticuloendothelial System (RES) of the liver, lung, and spleen of the body and hence drugs also. Resealed erythrocytes method of drugs delivery is secure and effective for drugs targeting specially for a longer period of time. This chapter will explain the different method of drug loading for resealed erythrocytes, their characterization, and applications in various therapies and associated health benefits.
APA, Harvard, Vancouver, ISO, and other styles
6

Guerra, Federico, and Alessandro Capucci. "Antiarrhythmics." In ESC CardioMed. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0036.

Full text
Abstract:
Antiarrhythmic drugs are the cornerstone of supraventricular and ventricular arrhythmias therapy. Despite the increasing interest in invasive and ablative approaches to treating many arrhythmias, such as atrial fibrillation and ventricular tachycardia, antiarrhythmic drugs are still widely used for both acute management and chronic prophylaxis. Unfortunately, many antiarrhythmic drugs currently available have a narrow therapeutic window and many issues regarding potential serious adverse effects, proarrhythmic properties, and multiorgan toxicity. The current Vaughan Williams classification of antiarrhythmic drugs is shown in a table. The aim this chapter is to provide basic information regarding the most used compounds in clinical practice.
APA, Harvard, Vancouver, ISO, and other styles
7

"Introduction to Pharmaceutical Care and Medication Adherence." In Design and Quality Considerations for Developing Mobile Apps for Medication Management. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-3832-6.ch001.

Full text
Abstract:
Pharmaceutical care is a concept that involves identifying, solving and preventing drug-related problems, such as drug interactions, with regards to a patient's drug therapy. Cancer patients are at high risk of drug interactions due to the complex pharmacological profiles and narrow therapeutic indices of anticancer drugs. Furthermore, these patients tend to consume complementary and alternative medicines, thus predisposing them to a risk of herb-drug interactions. This can impact their adherence to anticancer therapies. Various factors are involved in medication non-adherence, such as the cost of medications and patients' beliefs about the value of their treatments. There is a need to understand the impact of non-adherence and optimize intervention strategies from a macro-, meso-, and micro-level. Chapter 1 introduces the concept of pharmaceutical care and the impact of oncology drug interactions and medication non-adherence in patients with cancer. The chapter will also provide an insight to the factors influencing medication adherence and the intervention strategies that have targeted non-adherence.
APA, Harvard, Vancouver, ISO, and other styles
8

Djekic, Ljiljana. "Liposomes." In Advances in Medical Technologies and Clinical Practice. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-0751-2.ch002.

Full text
Abstract:
This chapter reviews the current progress in liposome based pharmaceuticals with particular emphasis on the carrier design, size, surface properties, drug delivery performances and therapeutic applications for different routes of administration. There were described selected examples of encapsulation of drug substances by liposomes which allowed improvement of therapeutic index of cytotoxic drugs (such as antineoplastics, antibiotics) or sustained drug release and reduction of the frequency of administration of analgesics and local anesthetics, and potentiate the immunogenicity of vaccines against hepatitis A and influenza. Furthermore, the performances of the marketed pharmaceuticals which represent pulmonary surfactant substituents (in the form of liposome vesicles) in premature infants and topical preparations with high molecular weight actives (e.g., heparin sodium) encapsulated in liposomes, were highlighted. The most important factors that affect the development of new drugs with this type of nanomaterials and their safety were commented.
APA, Harvard, Vancouver, ISO, and other styles
9

Villarrubia, Héctor J., and Nicholas P. Bell. "Hypotony." In Complications of Glaucoma Surgery. Oxford University Press, 2013. http://dx.doi.org/10.1093/oso/9780195382365.003.0023.

Full text
Abstract:
The overall goal of glaucoma filtering surgery is to lower the intraocular pressure (IOP) to a level where further optic nerve damage is prevented. There is a narrow therapeutic index for IOP that results in a delicate equilibrium between slowing and preventing progression of glaucoma while maintaining good visual function. Reaching that balance with glaucoma filtering surgery can be challenging, even in the best of hands performing uncomplicated surgery. In some patients the IOP becomes so low after trabeculectomy that damage to other ocular structures occurs, leading to impaired visual function. This condition is known as ocular hypotony and generally occurs at IOPs less than 6 mm Hg; however, we have seen cases of clinical hypotony with IOP as high as 12 mm Hg. The use of antifibrotics during trabeculectomy has greatly increased the success of trabeculectomy, but has also increased the risk of hypotony. Most glaucoma specialists refer to early postoperative hypotony as that which occurs within a period of 2 months or less after surgery regardless of its mechanism. Early postoperative hypotony occurs via 2 mechanisms: 1) decreased aqueous production , due to inflammation, ciliochoroidal or retinal detachment, or use of aqueous suppressants; or 2) excessive aqueous outflow , due to overfiltration, bleb leak, or a cyclodialysis cleft. Fortunately, most cases of early postoperative hypotony do not last longer than a few weeks and improve with conservative management. Although it is impossible to predict preoperatively which patient will develop early postoperative hypotony, preventative measures can be effective. Preventing and managing postoperative hypotony depends heavily upon operative and postoperative technique. Care should be taken in preoperative planning and intraoperative execution to avoid overfiltration and punctures of the conjunctival bleb that may turn into leaks. The use of nontoothed conjunctival forceps is essential. If the IOP remains too low for too long, the eye may develop hypotony maculopathy (see Chapter 22), a complication in which the macula develops choroidal folds due to chronically low IOP.
APA, Harvard, Vancouver, ISO, and other styles
10

Becker, Richard C., and Frederick A. Spencer. "Anticoagulants." In Fibrinolytic and Antithrombotic Therapy. Oxford University Press, 2006. http://dx.doi.org/10.1093/oso/9780195155648.003.0036.

Full text
Abstract:
Because of the narrow therapeutic index of warfarin and unfractionated heparin (UFH), monitoring their anticoagulant effects is required. On the other hand, lowmolecular- weight heparin (LMWH) and fibrinolytic agents need to be monitored only under certain circumstances. Although newer anticoagulants will not require routine monitoring for dose titration, a means to determine their systemic effects and individual (patient-specific) response to administration will likely have roles in clinical practice. The prothrombin time is used to monitor vitamin K antagonist therapy. This test is sensitive to the plasma concentrations (activity) of clotting factors II (prothrombin), V, VII, and X. Vitamin K antagonists affect the vitamin K–dependent factors II, VII, IX, and X, as well as proteins C, S, and Z. Thus, the prothrombin time does not reflect the effect of vitamin K antagonists on some factors (IX and proteins C, S, and Z) and is sensitive to others (factor V) (not directly influenced by treatment). The prothrombin time is not an ideal test for monitoring vitamin K antagonists; however, its simplicity and widespread availability have established its place in clinical practice. By convention, prothrombin times are now reported as international normalized ratios (INRs). This is the ratio of the patient’s prothrombin time to a control prothrombin time, raised to a power—the international sensitivity index (ISI). The latter reflects the calibration of the thromboplastin used for the prothrombin time testing to an internationally agreed upon standard. In many laboratories the reagent currently used is a recombinant thromboplastin, which has an ISI of 1.0 There are several cautions related to interpreting the results of prothrombin time tests that are worth monitoring. Since the test is sensitive to the level of factor V in the plasma, improper sample storage or delayed testing may cause loss of factor V (activity) and yield prothrombin time values above the expected range. High concentrations of heparin may also prolong the prothrombin time; this usually occurs when the sample is obtained within a few minutes of administering a bolus dose. Direct thrombin inhibitors, such as hirudin, bivalirudin, argatroban, and ximelagatran, may also prolong the prothrombin time to a variable degree.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Narrow therapeutic index drugs"

1

Rabbani, Naila, Paul John Thornalley, Maryam Al-Motawa, and Mingzhan Xue. "Vulnerabilities of the SARS-Cov-2 Virus to Proteotoxicity – Opportunity for Repurposed Chemotherapy of COVID-19 Infection." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0291.

Full text
Abstract:
The global pandemic of COVID-19 disease caused by infection with the SARS-CoV-2 Coronavirus, has produced an urgent requirement and search for improved treatments whilst effective vaccines are developed. A strategy for improved drug therapy is to increase levels of endogenous reactive metabolites for selective toxicity to SARS-CoV-2 by preferential damage to the viral proteome. Key reactive metabolites producing major quantitative damage to the proteome in physiological systems are: Reactive oxygen species (ROS) and the reactive glycating agent methylglyoxal (MG); cysteine residues and arginin
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Narrow therapeutic index drugs' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography